6161-65-5

Usage

Uses

Used in Pharmaceutical Research and Development:
2-Methoxy-6-methylbenzoic acid is utilized as a key intermediate in the synthesis of pharmaceutical drugs, contributing to the development of new medications. Its unique structure allows it to be a versatile building block in the creation of various drug molecules.
Used in Organic Synthesis:
In the field of organic synthesis, 2-Methoxy-6-methylbenzoic acid serves as a valuable intermediate for the production of a wide range of organic compounds. Its presence in the synthesis process can lead to the formation of new chemical entities with potential applications in various industries.
Used in Chemical Production:
2-Methoxy-6-methylbenzoic acid is used as a raw material in the chemical industry for the production of various compounds. Its unique properties make it suitable for use in the synthesis of specialty chemicals and other complex organic molecules.
It is important to handle 2-Methoxy-6-methylbenzoic acid with care and follow proper safety protocols during its use in research and industrial applications to ensure the safety of personnel and the environment.

InChI:InChI=1/C9H10O3/c1-6-4-3-5-7(12-2)8(6)9(10)11/h3-5H,1-2H3,(H,10,11)

Upstream product

• 38197-43-2 2-bromo-3-methylanisole 
• 54884-55-8 2-methoxy-6-methyl-benzaldehyde 
• 79383-44-1 methyl 2-methyl-6-methoxybenzoate 
• 139583-90-7 2-methoxy-6-methylbenzamide 
• 567-61-3 2-hydroxy-6-methylbenzoic acid 
• 77-78-1 dimethyl sulfate 
• 2944-49-2 2,3-dimethylanisole 
• 6520-83-8 ethyl 2-methoxy-6-methylbenzoate 
• 125023-39-4 C₁₀H₁₂N₂O₃ 
• 579-75-9 2-Methoxybenzoic acid 
• 74-88-4 methyl iodide 
• 103562-89-6 2-methoxy-6-methyl-N-<2-(diethylamino)ethyl>-N-ethylbenzamide 
• 124-38-9 carbon dioxide 
• 100-84-5 1-methoxy-3-methyl-benzene 

Downstream Products

• 567-61-3 2-hydroxy-6-methylbenzoic acid 
• 50463-84-8 2-methoxy-6-methylbenzoyl chloride 
• 1137-31-1 2-carboxy-3-methoxybenzene-1-acetic acid 
• 70887-47-7 2-(2-Hydroxyethyl)-6-methoxy-benzoesaeure 
• 220901-25-7 3-bromo-6-methoxy-2-methylbenzoic acid 
• 36640-14-9 2-Methoxy-6-<2-(4-methoxyphenyl)ethyl>benzoic acid 
• 72216-29-6 2-ethyl-6-methoxybenzoic acid 
• 712273-62-6 5-bromo-2-methoxy-6-methyl-benzoic acid chloride 
• 79383-44-1 methyl 2-methyl-6-methoxybenzoate 
• 90798-59-7 methyl 6-dibromomethyl-2-methoxybenzoate 
• 133379-09-6 methyl 5-bromo-2-methoxy-6-methylbenzoate 
• 133379-08-5 methyl 3-bromo-2-(bromomethyl)-6-methoxybenzoate 
• 943595-13-9 methyl 2-(bromomethoxy)-6-methoxybenzoate 
• 1192172-68-1 ethyl 5-bromo-4-methylbenzofuran-2-carboxylate 

Relevant academic research and scientific papers

Preparation method of 2-methoxy-6-methylbenzoic acid

The invention discloses a synthesis process of 2-methoxy-6-methylbenzoic acid, which comprises the following steps: (1) reduction hydrogenation reaction: by taking 2-methyl-6-nitrobenzoic acid or methyl 2-methyl-6-nitrobenzoate as a raw material, methanol as a solvent, hydrogen as a hydrogen source and palladium on carbon or platinum on carbon as a catalyst, carrying out hydrogenation reduction to prepare 2-amino-6-methylbenzoic acid or methyl 2-amino-6-methylbenzoate; (2) diazotization, hydrolysis and esterification one-pot reaction: by taking the reduction product as a raw material, and methanol as a solvent, performing diazotization, hydrolysis and esterification reaction under the action of a diazotization reagent to prepare methyl 2-hydroxy-6-methylbenzoate; (3) methylation reaction: with methyl 2-hydroxy-6-methylbenzoate as a raw material and dimethyl sulfate as a methylation reagent, carrying out methylation reaction in the presence of alkali to prepare methyl 2-methoxy-6-methylbenzoate; and (4) hydrolysis reaction: mixing the methyl 2-methoxy-6-methylbenzoate with alkali and water, conducting heating for hydrolysis, conducting cooling after the reaction is completed, adjusting the pH value to 1-3 by using acid, separating out a product, and conducting filtering and drying to obtain the 2-methoxy-6-methylbenzoic acid.

HISTONE ACETYLTRANSFERASE ACTIVATORS AND COMPOSITIONS AND USES THEREOF

The invention provides pharmaceutical compositions and methods for treating cancer, neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein by administering a HAT modulator and a HDAC modulator to a subject.

HISTONE ACETYLTRANSFERASE ACTIVATORS AND USES THEREOF

The invention provides compounds and compositions comprising compounds that modulate histone acyl transferase (HAT). The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a compound that modulates HAT to a subject.

Synthesis of (+)-varitriol analogues via novel and versatile building blocks based on julia olefination

The synthesis of (+)-varitriol (1) analogues was achieved through, the use of Julia olefination. The potential anticancer properties of 1 coupled with, our interest in developing building blocks that enable olefin formation under the Julia protocol constitute the basis of our research project. Efforts are aimed at the synthesis of building blocks 2 and 3 and to explore their use towards the synthesis of (+)-varit:riol analogues. Herein, we would, like to present the synthesis of building block 3 and its ability to react with variety of substituted aromatic-, heterocyclic- and carbohydrate-derived aldehydes to yield alkene 6 in moderate to good yields with E as the major isomer. The successful, coupling of 2 with (furanoside moieties) aldehydes 5k, 5m and 5n in particular and the obtainment of compound 23 reflect the promise associated with the new strategy.

Original preparation of conjugates for antibody production against Amicoumacin-related anti-microbial agents

Amicoumacins are natural products with potent anti-ulcerogenic and anti-bacterial activities, and have been isolated from different Bacillus genera. They belong to a family of 3,4-dihydroisocoumarin derivatives bearing hydroxylated amino acid side chains.

Titanocene(III) chloride mediated radical-induced synthesis of 3,4-dihydroisocoumarins: synthesis of (±)-hydrangenol, (±)-phyllodulcin, (±)-macrophyllol and (±)-thunberginol G

A radical-promoted synthesis of 3,4-dihydroisocoumarins has been achieved in moderate to good yields using titanocene(III) chloride (Cp2TiCl) as the radical initiator. The total synthesis of four naturally occurring dihydrocoumarins hydrangenol, phyllodulcin, macrophyllol and thunberginol G has been accomplished using the radical technology. Cp2TiCl was prepared in situ from commercially available titanocene dichloride (Cp2TiCl2) and Zn-dust in THF under argon.

First general, direct, and regioselective synthesis of substituted methoxybenzoic acids by ortho metalation

(Chemical Equation Presented) New general methodology of value in aromatic chemistry based on ortho-metalation sites in o-, m-, and p-anisic acids (1-3) (Scheme 1) is described. The metalation can be selectively directed to either of the ortho positions by varying the base, metalation temperature, and exposure times. Metalation of o-anisic acid (1) with s-BuLi/TMEDA in THF at -78°C occurs exclusively in the position adjacente to the carboxylate. On the other hand, a reversal of regioselectivity is observed with n-BuLi/t-BuOK. With LTMP at 0°C, the two directors of m-anisic acid (2) function in concert to direct introduction of the metal between them while n-BuLi/t-BuOK removes preferentially the proton located ortho to the methoxy and para to the carboxylate (H-4). s-BuLi/TMEDA reacts with p-anisic acid (3) exclusively in the vicinity of the carboxylate. According to these methodologies, routes to very simple methoxybenzoic acids with a variety of functionalities that are not easily accessible by other means have been developed (Table 1).

PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES

The present invention relates to polyphenol-like compounds that are useful for inhibiting VCAM-1 expression, MCP-1 expression and/or SMC proliferation in a mammal. The disclosed compounds are useful for regulating markers of inflammatory conditions, including vascular inflammation, and for treatment and prevention of inflammatory and cardiovascular diseases and related disease states.

QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS

The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S

The invention provides compounds of the formula (I), or salts, tautomers, N-oxides or solvates thereof wherein: R1 is selected from: (a) 2,6-dichlorophenyl; (b) 2,6-difluorophenyl; (c) a 2,3,6-trisubstituted phenyl group wherein the substituents for the phenyl group are selected from fluorine, chlorine, methyl and methoxy; (d) a group R0; (e) a group R a; (f) a group Rlb; (g) a group Rlc; (h) a group Rld; and 0) 2,6-difluorophenylamino ; wherein R )0υ, r R> llaa, T Rj I1bD, T R) I1cC, r R> Iidα, r R?2zaa, r R>22bD and RJ are as defined in the claims. The compounds have activity as inhibitors of cdk kinase (such as cdkl or cdk2) and glycogen synthase kinase-3 activity.